Nov 20 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved Alnylam Pharmaceuticals Inc’s gene silencing drug as a treatment for patients with a rare inherited disorder.
The drug was approved to treat acute hepatic porphyria, a genetic disorder that can cause seizures and back pains. (bit.ly/37oqz9Z)
The drug, known as Givlaari, uses a mechanism known as RNA interference to target and “silence” specific genetic material, blocking the production of the deadly protein that causes the disease.
Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva